27.26
1.98%
-0.551
After Hours:
27.4492
0.1876
+0.69%
Virtus LifeSci Biotech Clinical Trials ETF stock is currently priced at $27.26, with a 24-hour trading volume of 3,631.
It has seen a -1.98% decreased in the last 24 hours and a +5.91% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $27.82 pivot point. If it approaches the $27.52 support level, significant changes may occur.
Previous Close:
$27.81
Open:
$27.9
24h Volume:
3,631
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.68%
1M Performance:
+5.91%
6M Performance:
+42.58%
1Y Performance:
+11.07%
Virtus LifeSci Biotech Clinical Trials ETF Stock (BBC) Company Profile
Name
Virtus LifeSci Biotech Clinical Trials ETF
Sector
Industry
Phone
888-383-0553
Address
-
Virtus LifeSci Biotech Clinical Trials ETF Stock (BBC) Latest News
Long Term Trading Analysis for (BBC) - Stock Traders Daily
Stock Traders Daily
Hong Kong Approves First Bitcoin and Ether ETFs: A Game-Changer in the Crypto Market - The Globe and Mail
The Globe and Mail
Hong Kong Approves First Bitcoin and Ether ETFs: A Game-Changer in the Crypto Market - The Globe and Mail
The Globe and Mail
Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Trading Down 2% - Defense World
Defense World
(BBC) Trading Report - Stock Traders Daily
Stock Traders Daily
Canadian Ether ETFs Opportunity if SEC approves Spot Ether in U.S. - The Globe and Mail
The Globe and Mail
Virtus LifeSci Biotech Clinical Trials ETF Stock (BBC) Financials Data
There is no financial data for Virtus LifeSci Biotech Clinical Trials ETF (BBC). Check out other stocks for more information.
About Virtus LifeSci Biotech Clinical Trials ETF
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index.
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Cap:
|
Volume (24h):